The treatment of typhoid fever

Current Opinion in Infectious Diseases

Volumn 9, Issue 5, 1996, Pages 298-302

  White, Nicholas J ^a   Parry, Christopher M ^a  

^a Centre for Tropical Diseases Vietnam   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; FLEROXACIN; FURAZOLIDONE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

HUMAN; ORAL DRUG ADMINISTRATION; SALMONELLA TYPHI; SHORT SURVEY; STRAIN DIFFERENCE; TYPHOID FEVER; VIET NAM;

EID: 0029800643     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199610000-00003     Document Type: Short Survey

References (40)

1. Pang T, Bhutta ZA, Finlay BB, Altwegg M: Typhoid fever and other salmonellosis: a continuing challenge. Trends Microbiol 1995, 3:253-255.
2. Olarte J, Galindo E: Salmonella typhi resistant to chloroamphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob Agents Chemother 1973, 4:597-601.
3. Paniker CKJ, Vimala KN: Transferable chloramphenicol resistance in Salmonella typhi. Nature 1972, 239:109-110.
4. Pillay N, Adams EB, North-Coombes D: Comparative trial of amoxycillin and chloramphenicol in treatment of typhoid fever in adults. Lancet 1975, ii:333-334.
5. Herzog C: Chemotherapy of typhoid fever. Infection 1976, 4:166-173.
6. Corrado ML, DuPont HL, Cooperstock M, Fekety R, Murray DM: Evaluation of new anti-infective drugs for the treatment of typhoid fever. Clin Infect Dis 1992, 15:S236-S240.
7. Gulati S, Marwaha RK, Prakash D, Ayyagari A, Singhi S, Kumar L, Singhi P, Walia BN: Multidrug-resistant Salmonella typhi - a need for therapeutic reappraisal. Ann Trop Paediatr 1992, 12:137-141.
8. Soe GB, Overturf GD: Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins. Rev Infect Dis 1967, 9:719-736.
9. Islam A, Butler T, Nath SK, Alam NH. Stoeckel K, Houser HB, Smith AL: Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. J Infect Dis 1988, 158:742-747.
10. Lasserr R, Sangalang RP, Santiago L: Three-day treatment of typhoid fever with two different dosages of ceftriaxone, compared to 14-day therapy with chloramphenicol: a randomized trial. J Antimicrob Chemother 1991, 28:765-772.
11. Uwaydah AK, Al Soub H, Matar I: Randomized prospective study comparing two dosage regimens of ciprofloxacin for the treatment of typhoid fever. J Antimicrob Chemother 1992, 30:707-711.
12. Islam S, Butler T, Kabir I, Alam NH: Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days; a randomized clinical trial. Antimicrob Agents Chemother 1993, 37:1572-1575.
13. Arnold K, Hong CS, Newlan R, Zavala-Truijillo I, Kadio A, Barros MADO, Garns SD: Randomized comparative study of fleroacin and chloramphenicol in typhoid fever. Am J Med 1993, 94(suppl 3A): 195s-199s.
14. Mirza SH, Beeching NJ, Hart CA. Multidrug resistant typhoid: a global problem. J Med Microbiol 1996, 44:317-319. A short summary of the global emergence of multidrug-resistant typhoid since 1987.
15. Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ: Multidrug resistant typhoid fever in children: presentation and clinical features. Rev Infect Dis 1991, 13:832-836.
16. Du Pont H: Quinolones in Salmonella typhi infection. Drugs 1993, 45(suppl 3):119-124.
17. Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, Hyams KC: Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993, 12:907-910.
18. Hien TT, Duong NM, Ha HD, Hoa NTT, Diep TS, Phi LT, Arnold K: A randomised comparative study of fleroxacin and ceftriaxone in enteric fever. Trans R Soc Trop Med Hyg 1994, 88:464-465.
19. Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, Diep TS, Day NP, Hien TT, White NJ: Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994, 38:1716-1720.
20. Alam MN, Haq SA, Das KK, Baral PK, Mazid MN, Siddique RU, Rahman KM, Hasan Z, Khan MAS, Dutta P: Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Am J Trop Med Hyg 1995, 53:306-311. This study showed that ciprofloxacin was equally effective at a dose of 500 mg twice a day for 10 and 14 days in 69 adults with enteric fever in Bangladesh, 52% of whom had multidrug-resistant infections.
21. Hien TT, Bethell DB, Hoa NT, Wain J, Diep TS, Phi LT, Cuong BM, Duong NM, Thanh PT, Walsh AL et al.: Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995, 20:917-923. During an epidemic of multidrug-resistant typhoid in southern Viel Nam an open paired randomized study compared ofloxacin 10mg/kg a day for 5 days with 15mg/kg daily for 3 days in 438 patients with uncomplicated typhoid fever, of these 286 were children, 228 were blood culture-positive and 91% of the S. typhi were multidrug resistant. There was only one treatment failure in a patient who took only one dose of ofloxacin. Of these patients 70% were followed up at 1 month and there were no carriers identified on the basis of culture of a single stool sample.
22. Duong NM, Vinh Chau NV, Van Anh DC, Hoa NTT, Hoai Tam DT, Ho DT, Hien TT, Arnold K: Short course fleroxacin in the treatment of typhoid fever. JAMA Southeast Asia 1995, 11:6-11. In this study 63 culture-positive adults responded equally well to 400 mg fleroxacin once a day for 3 or 5 days; 84% of the S. typhi were multidrug resistant. Mean fever clearance was 89 h in the 3-day group and 82 h in those treated for 5 days. The one possible relapse was in a patient treated for 5 days.
23. Vinh H, Wain J, Nga CN, Chinh MT, Bethell DB, Hoa NTT, Diep TS, Dung NM, While NJ: Two or three days ofloxacin for the treatment of multi-drug resistant typhoid fever in children. Antimicrob Agents Chemother 1996, 40:958-961. In this study short courses of either 2 or 3 days of ofloxacin (15mg/kg/day) were compared in 100 children with typhoid fever; 86% of isolates were multidrug resistant. Six of 53 children treated for 2 days were clinical failures compared with two of the 47 treated for 3 days. Fever clearance was about 100 h in both groups. One child had a suspected relapse and one carrier was identified.
24. Bhutta ZA, Khan IA, Molla AM: Therapy of multi-drug resistant typhoid fever with oral cefixime vs intravenous ceftriaxone. Pediatr Infect Dis J 1994, 13:990-994.
25. Girgis NI, Kilpatrick ME, Fand Z, Sultan Y, Podgore JK: Cefixime in the treatment of enteric fever in children. Drugs Exptl Clin Res 1994, 19:47-49.
26. Acharya G, Crevoisier C, Butler T, Ho M, Tiwari M, Stoeckel K, Bradley CA: Pharmacokinetics of ceftriaxone in patients with typhoid fever. Antimicrob Agents Chemother 1994, 38:2415-2418.
27. Gotuzzo E, Echevarria J, Carrillo C, Sanchez J, Grados P, Maguina C, Du Pont HL: Randomized comparison of aztreonam and chloramphenicol in treatment of typhoid fever. Antimicrob Agents Chemother 1994, 38:558-562.
28. Wallace MR, Yousif AA, Habib HF. Tribble DR: Azithromycin and typhoid. Lancet 1994, 343:1497-1498.
29. Sethuraman S, Mahamood M, Kareem S: Furazolidone in multi-resistant childhood typhoid fever. Ann Trop Paediatr 1994, 14:321-324.
30. Bethell DB, Hien TT, Phi LT, Day NPJ, Vinh H, Dung NM, Len NV, Chuong LV, White NJ: The effects on growth of single short courses of fluoroquinolones. Arch Dis Child 1996, 74:44-46. In this study 326 Vietnamese children were followed up for 2 years after receiving either ciprofloxacin (97 mg/kg given over 7 days) or ofloxacin (45-50 mg/kg given over 3-5 days) for treatment during the control of an epidemic of multidrug-resistant typhoid fever. Growth velocity and weight for height were compared with an age-matched control group of 223 children from the same locality. There was no evidence of acute joint toxicity or joint symptoms attributable to the fluoroquinolones and there were no differences in growth or the expected weight or height measurements between the three groups of children over the 2-year period.
31. Schaad UB, Mohammed AS, Yannick A, Dagan R, Green SDR, Peltola H, Rubio TT, Smith AL, Dieter A: Use of fluoroquinolones in paediatrics: a consensus report of an International Society of Chemotherapy commission. Paediatr Infect Dis J 1995, 14:1-9.
32. Bavdekar A, Bhave M: Ciprofloxacin in typhoid fever. Ind J Paediatr 1991, 58:335-339.
33. Cheesbrough JS, Mwema FI, Green SDR, Tillotson GS: Quinolones in children with invasive salmonellosis [Letter]. Lancet 1991, 338:127.
34. Gendrel D, Raymond J, Legall MA, Bergeret M, Badoual J: Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. Eur J Clin Microbiol Infect Dis 1993, 12:209-211.
35. Carbon C, Weber P, Levy M, Boussougant Y, Cerf M: Short-term ciprofloxacin treatment for typhoid fever. J Infect Dis 1987, 155:833.
36. Umasander S, Wall RA, Berger J: A case of ciprofloxacin resistant typhoid fever. Commun Dis Rep 1992, 2:R139-R140.
37. Daga MK, Sarin K, Sarkar R. A study of culture positive multi-drug resistant enteric fever - changing patterns and emerging resistance to ciprofloxacin. J Ass Phys India 1994, 42:599-600.
38. Rowe B, Ward LR, Threlfall EJ: Ciprofloxacin-resistant Salmonella typhi in the UK [Letter]. Lancet 1995, 346:1302. Further reports of ciprofloxacin-resistant S. typhi in nine patients returning to the UK from the Indian sub-continent during 1994 and 1995. Resistance was not invariably associated with resistance to other antibiotics.
39. Brown NM, Millar MR, Frost JA, Rowe B: Ciprofloxacin resistance in Salmonella paratyphi A. J Antimicrob Chemother 1994, 33:1258-1259.
40. Brown JC, Shanahan PMA, Jesudason MV, Thomson CJ, Aymes SGB: Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother 1996, 37:891-900. In this study 12 isolates of S. typhi from Vellore, India with reduced susceptibility to 4-quinolones (MIC of ciprofloxacin 0.25μg/ml) were found to have mutations in the 'quinolone resistance determining region' of gyrA. In nine isolates phenylalanine was substituted for serine at position 83 of gyrA, in one tyrosine was substituted for aspartate at position 87 and the final isolate had a combination of both mutations. These are similar to the mutations seen in other ciprofloxacin-resistant enterobactericeae.